MX2021005189A - Uso de tivozanib para tratar sujetos con cancer refractario. - Google Patents
Uso de tivozanib para tratar sujetos con cancer refractario.Info
- Publication number
- MX2021005189A MX2021005189A MX2021005189A MX2021005189A MX2021005189A MX 2021005189 A MX2021005189 A MX 2021005189A MX 2021005189 A MX2021005189 A MX 2021005189A MX 2021005189 A MX2021005189 A MX 2021005189A MX 2021005189 A MX2021005189 A MX 2021005189A
- Authority
- MX
- Mexico
- Prior art keywords
- tivozanib
- refractory cancer
- treat subjects
- refractory
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Abstract
Se describe un método para tratar el cáncer, por ejemplo, cáncer refractario, con tivozanib. Los métodos descritos incluyen, por ejemplo, administrar tivozanib como terapia de segunda o tercera línea a sujetos que padecen carcinoma de células renales avanzado refractario cuando las terapias tradicionales, así como las terapias dirigidas e inmunoncologicas más recientes no han tratado adecuadamente al sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862756033P | 2018-11-05 | 2018-11-05 | |
PCT/US2019/059904 WO2020097106A1 (en) | 2018-11-05 | 2019-11-05 | Use of tivozanib to treat subjects with refractory cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021005189A true MX2021005189A (es) | 2022-01-18 |
Family
ID=70612200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005189A MX2021005189A (es) | 2018-11-05 | 2019-11-05 | Uso de tivozanib para tratar sujetos con cancer refractario. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20220000858A1 (es) |
EP (1) | EP3876934A4 (es) |
AU (1) | AU2019375972A1 (es) |
BR (1) | BR112021008606A2 (es) |
CA (1) | CA3118690A1 (es) |
CL (1) | CL2021001172A1 (es) |
EA (1) | EA202191273A1 (es) |
IL (1) | IL282869A (es) |
MX (1) | MX2021005189A (es) |
WO (1) | WO2020097106A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023096651A1 (en) | 2021-11-26 | 2023-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treating bile duct cancers with tivozanib |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998047873A1 (fr) | 1997-04-18 | 1998-10-29 | Kirin Beer Kabushiki Kaisha | Procede de production de derives de quinolone |
DK1382604T3 (da) | 2001-04-27 | 2006-04-18 | Kirin Brewery | Quinolinderivater med en azolylgruppe og quinazolinderivater |
WO2004035572A1 (ja) | 2002-10-21 | 2004-04-29 | Kirin Beer Kabushiki Kaisha | N−{2−クロロ−4−[(6,7−ジメトキシ−4−キノリル)オキシ]フェニル}−n’−(5−メチル−3−イソキサゾリル)ウレアの塩の結晶形 |
US7736861B1 (en) * | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
US7998973B2 (en) * | 2009-11-13 | 2011-08-16 | Aveo Pharmaceuticals, Inc. | Tivozanib and temsirolimus in combination |
ES2899457T3 (es) * | 2014-02-04 | 2022-03-11 | Pfizer | Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer |
WO2015134605A1 (en) * | 2014-03-05 | 2015-09-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
-
2019
- 2019-11-05 AU AU2019375972A patent/AU2019375972A1/en active Pending
- 2019-11-05 EP EP19882866.7A patent/EP3876934A4/en active Pending
- 2019-11-05 EA EA202191273A patent/EA202191273A1/ru unknown
- 2019-11-05 US US17/289,913 patent/US20220000858A1/en active Pending
- 2019-11-05 WO PCT/US2019/059904 patent/WO2020097106A1/en unknown
- 2019-11-05 BR BR112021008606-4A patent/BR112021008606A2/pt unknown
- 2019-11-05 CA CA3118690A patent/CA3118690A1/en active Pending
- 2019-11-05 MX MX2021005189A patent/MX2021005189A/es unknown
-
2021
- 2021-05-03 IL IL282869A patent/IL282869A/en unknown
- 2021-05-04 CL CL2021001172A patent/CL2021001172A1/es unknown
-
2022
- 2022-04-14 US US17/720,619 patent/US11504365B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CL2021001172A1 (es) | 2021-10-22 |
WO2020097106A1 (en) | 2020-05-14 |
US20220000858A1 (en) | 2022-01-06 |
EP3876934A1 (en) | 2021-09-15 |
US20220233516A1 (en) | 2022-07-28 |
BR112021008606A2 (pt) | 2021-08-03 |
US11504365B2 (en) | 2022-11-22 |
EP3876934A4 (en) | 2022-08-03 |
EA202191273A1 (ru) | 2021-09-15 |
IL282869A (en) | 2021-06-30 |
CA3118690A1 (en) | 2020-05-14 |
AU2019375972A1 (en) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023007193A (es) | Inhibidores de enpp1 y su uso para el tratamiento del cancer. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
PH12016502354A1 (en) | Pharmaceutical composition | |
MX2020009773A (es) | Terapia de combinacion. | |
WO2020086726A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
MX2020001727A (es) | Terapia de combinacion. | |
WO2018102687A3 (en) | Combination therapy for treating cancer | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
JOP20190008A1 (ar) | علاج ومنع اضطرابات النوم | |
MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
MX2019013862A (es) | Terapia de combinacion. | |
MX2021013608A (es) | Composiciones y métodos de fabricacion de celulas t. | |
NZ712691A (en) | C. novyi for the treatment of solid tumors in humans | |
WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
MX2021008972A (es) | Terapia de combinacion de quelante metalico para el tratamiento del cancer. | |
MX2021015401A (es) | Terapia de combinacion que comprende un conjugado de farmacoanticuerpo anti-cd25 y otro agente. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
MX2021005189A (es) | Uso de tivozanib para tratar sujetos con cancer refractario. | |
MX2021006778A (es) | Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. | |
MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. |